Botulinum Toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin

Pain

Volumn 130, Issue 1-2, 2007, Pages 76-83

  Tugnoli, Valeria ^a   Capone, Jay Guido ^a   Eleopra, Roberto ^a   Quatrale, Rocco ^a   Sensi, Mariachiara ^a   Gastaldo, Ernesto ^a   Tola, Maria Rosaria ^a   Geppetti, Pierangelo ^a,b  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Botulinum toxin; Capsaicin; Neurogenic inflammation; Pain

Indexed keywords

BOTULINUM TOXIN A; CAPSAICIN; SODIUM CHLORIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROPATHIC PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PRIORITY JOURNAL; SKIN BLOOD FLOW; SKIN TEST; THERMAL STIMULATION; VASODILATATION; VISUAL ANALOG SCALE;

ADULT; BOTULINUM TOXIN TYPE A; CAPSAICIN; ERYTHEMA; FEMALE; HEAT; HUMANS; MALE; MIDDLE AGED; NEURALGIA; NEUROMUSCULAR AGENTS; PAIN THRESHOLD; SKIN; VASODILATION;

EID: 34249742661     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2006.10.030     Document Type: Article

References (56)

1. Allam N., Brasil-Neto J.P., Brown G., and Tomaz C. Injection of Botulinum toxin type A produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain 21 (2005) 182-184
2. Amann R., and Maggi C.A. Ruthenium red as a capsaicin antagonist. Life Sci 49 (1991) 849-856
3. Aoki K.R. Physiology and pharmacology of therapeutic botulinum neurotoxins. Curr Probl Dermatol 30 (2002) 107-116
4. Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43 (2003) S9-S15
5. Baron R., Wasner G., Borgstedt R., Hastedt E., Schulte H., Binder A., et al. Effect of sympathetic activity on capsaicin-evoked pain, hyperalgesia, and vasodilatation. Neurology 52 (1999) 923-932
6. Blersch W., Schulte-Mattler W.J., Przywara S., May A., Bigalke H., and Wohlfarth K. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 205 (2002) 59-63
7. Borodic G.E., Acquadro M., and Johnson E.A. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs 10 (2001) 1531-1544
8. Borodic G.E., and Acquadro M.A. The use of botulinum toxin for the treatment of chronic facial pain. J Pain 3 (2002) 21-27
9. Brisinda C., Bentivoglio A.R., Maira G., and Albanese A. Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. Mov Disord 19 Suppl 8 (2004) S146-S156
10. Bushara K.O., and Park D.M. Botulinum toxin and sweating. J Neurol Neurosurg Psychiatry 57 (1994) 1437-1438
11. Caputi C.A. Effectiveness of BoNT-A in the treatment of migraine and its ability to repress CGRP release. Headache 44 (2004) 837-838
12. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., and Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (1997) 816-824
13. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petersen-Zeitz K.R., et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288 (2000) 306-313
14. Cheshire W.P., Abashian S.W., and Mann J.D. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59 (1994) 65-69
15. Cui M., Khanijou S., Rubino J., and Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107 (2004) 125-133
16. Cui M., Li Z., You S., Khanijou S., and Aoki K. Mechanism of the antinociceptive effect of subcutaneous Botox inibition of peripheral and central nociceptive processing. Naunyn Schmiedebergs Arch Pharmacol 365 (2002) R17
17. Davis J.B., Gray J., Gunthorpe M.J., Hatcher J.P., Davey P.T., Overend P., et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405 (2000) 183-187
18. Dodick D.W., Mauskop A., Elkind A.H., DeGryse R., Brin M.F., and Silberstein S.D. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45 (2005) 315-324
19. Drummond P.D. Noradrenaline increases hyperalgesia to heat in skin sensitized by capsaicin. Pain 60 (1995) 311-315
20. Drummond P.D. Enhancement of thermal hyperalgesia by alpha-adrenoceptors in capsaicin-treated skin. J Autonom Nerv Syst 69 (1998) 96-102
21. Durham P.L., Cady R., and Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44 (2004) 35-42
22. Erbguth F.J., and Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison". Neurology 53 (1999) 1850-1853
23. Evers S., Vollmer-Haase J., Schwaag S., Rahmann A., Husstedt I.W., and Frese A. Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephalalgia 24 (2004) 838-843
24. Freund B., Schwartz M., and Symington J.M. Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 38 (2000) 466-471
25. Gazerani P., Staahl C., Drewes A.M., and Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitisation. Pain 122 (2006) 315-325
26. Geppetti P., and Holzer P. Neurogenic Inflammation (1996), CRC Press, Boca Raton
27. Gobel H., Heinze A., Heinze-Kuhn K., and Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 91 (2001) 195-199
28. Greene P., Kang U., Fahn S., Brin M., Moskowitz C., and Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40 (1990) 1213-1218
29. Gruener G., and Dyck P.J. Quantitative sensory testing: methodology, applications, and future directions. J Clin Neurophysiol 11 (1994) 568-583
30. Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 43 (1991) 143-201
31. Ishikawa H., Mitsui Y., Yoshitomi T., Mashimo K., Aoki S., Mukuno K., et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Nippon Ganka Gakkai Zasshi 105 (2001) 218-222
32. Jabbari B., Maher N., and Difazio M.P. Botulinum toxin a improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med 4 (2003) 206-210
33. Kramer H.H., Angerer C., Erbguth F., Schmelz M., and Birklein F. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 250 (2003) 188-193
34. LaMotte R.H., Lundberg L.E., and Torebjork H.E. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol 448 (1992) 749-764
35. Lin Q., Xiaoju Z., Li F., and Willis W.D. Sympathetic modulation of acute cutaneous flare induced by intradermal injection of capsaicin in anesthetized rats. J Neurophysiol 89 (2003) 853-861
36. Maggi C.A., and Meli A. The sensory-efferent function of capsaicin-sensitive sensory neurons. Gen Pharmacol 19 (1988) 1-43
37. Montecucco C., and Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 13 (1994) 1-8
38. Morenilla-Palao C., Planells-Cases R., Garcia-Sanz N., and Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 279 (2004) 25665-25672
39. Morris J.L., Jobling P., and Gibbins I.L. Botulinum neurotoxin A attenuates release of norepinephrine but not NPY from vasoconstrictor neurons. Am J Physiol Heart Circ Physiol 283 (2002) H2627-H2635
40. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 85 (2000) 101-105
41. Ren Y., Zou X., Fang L., and Lin Q. Sympathetic modulation of activity in Adelta- and C-primary nociceptive afferents after intradermal injection of capsaicin in rats. J Neurophysiol 93 (2005) 365-377
42. Saper J.R. Botulinum toxin and chronic facial pain. J Pain 3 (2002) 2
43. Schmelz M., Michael K., Weidner C., Schmidt R., Torebjork H.E., and Handwerker H.O. Which nerve fibers mediate the axon reflex flare in human skin?. Neuroreport 11 (2000) 645-648
44. Serra J., Campero M., and Ochoa J. Flare and hyperalgesia after intradermal capsaicin injection in human skin. J Neurophysiol 80 (1998) 2801-2810
45. Silberstein S.D. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother 2 (2001) 1649-1654
46. Simone D.A., Baumann T.K., and LaMotte R.H. Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. Pain 38 (1989) 99-107
47. Simpson L.L. The origin, structure and pharmacological activity of botulinum toxin. Pharmacol Rev 33 (1981) 155-188
48. Szallasi A. Vanilloid (capsaicin) receptors in health and disease. Am J Clin Pathol 118 (2002) 110-121
49. Troost B.T. Botulinum toxin type A (Botox) in the treatment of migraine and other headaches. Expert Rev Neurother 4 (2004) 27-31
50. Tsui J.K., Eisen A., Stoessl A.J., Calne S., and Calne D.B. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2 (1986) 245-247
51. Verdugo R., and Ochoa J.L. Quantitative somatosensory thermotest. A key method for functional evaluation of small calibre afferent channels. Brain 115 (1992) 893-913
52. Voller B., Sycha T., Gustorff B., Schmetterer L., Lehr S., Eichler H.G., et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 61 (2003) 940-944
53. Wasner G., Binder A., Kopper F., and Baron R. No effect of sympathetic sudomotor activity on capsaicin-evoked ongoing pain and hyperalgesia. Pain 84 (2000) 331-338
54. Welch M.J., Purkiss J.R., and Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38 (2000) 245-258
55. Wissel J., Muller J., Dressnandt J., Heinen F., Naumann M., Topka H., et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 20 (2000) 44-49
56. Yarnitsky D., Sprecher E., Zaslansky R., and Hemli J.A. Heat pain thresholds: normative data and repeatability. Pain 60 (1995) 329-332